SEATTLE--(BUSINESS WIRE)--Northstar Neuroscience, Inc. (Nasdaq:NSTR) today reported that through March 31, 2007, the Company had randomized 142 patients in its EVEREST pivotal clinical trial for recovery of hand and arm function following a stroke, and expects to complete randomization of the last patient in the trial in the second quarter of this year. Planned investments in EVEREST, three additional clinical trials, and the Company’s Renova™ Cortical Stimulation System resulted in a net loss of $6.6 million for the quarter ended March 31, 2007. This compares to a net loss of $4.3 million for the quarter ended March 31, 2006. The Company also reported cash and investments of $100.5 million at March 31, 2007 compared to $105.3 million at December 31, 2006.
